MX2010012101A - Metodo de tratamiento del cancer usando un inhibidor de cmet y axl y un inhibidor de erbb. - Google Patents
Metodo de tratamiento del cancer usando un inhibidor de cmet y axl y un inhibidor de erbb.Info
- Publication number
- MX2010012101A MX2010012101A MX2010012101A MX2010012101A MX2010012101A MX 2010012101 A MX2010012101 A MX 2010012101A MX 2010012101 A MX2010012101 A MX 2010012101A MX 2010012101 A MX2010012101 A MX 2010012101A MX 2010012101 A MX2010012101 A MX 2010012101A
- Authority
- MX
- Mexico
- Prior art keywords
- compound
- erbb
- cmet
- lapatinib
- inhibitor
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title claims abstract description 45
- 206010028980 Neoplasm Diseases 0.000 title claims abstract description 27
- 201000011510 cancer Diseases 0.000 title claims abstract description 18
- 238000000034 method Methods 0.000 title abstract description 20
- 150000001875 compounds Chemical class 0.000 claims abstract description 137
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 claims abstract description 31
- 150000003839 salts Chemical class 0.000 claims abstract description 30
- 101710100969 Receptor tyrosine-protein kinase erbB-3 Proteins 0.000 claims abstract description 23
- 102000056372 ErbB-3 Receptor Human genes 0.000 claims abstract description 3
- 101710100968 Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 claims abstract 2
- 210000004072 lung Anatomy 0.000 claims description 20
- 229960000575 trastuzumab Drugs 0.000 claims description 18
- 238000011282 treatment Methods 0.000 claims description 17
- 208000026310 Breast neoplasm Diseases 0.000 claims description 15
- 206010006187 Breast cancer Diseases 0.000 claims description 14
- 230000002496 gastric effect Effects 0.000 claims description 12
- -1 morpholino, piperidinyl Chemical group 0.000 claims description 7
- 210000000481 breast Anatomy 0.000 claims description 6
- 239000003814 drug Substances 0.000 claims description 6
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical group C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 claims description 5
- 201000010536 head and neck cancer Diseases 0.000 claims description 4
- 208000014829 head and neck neoplasm Diseases 0.000 claims description 4
- 229960005395 cetuximab Drugs 0.000 claims description 3
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 3
- 229910052757 nitrogen Inorganic materials 0.000 claims description 3
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 3
- 230000002611 ovarian Effects 0.000 claims description 3
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 3
- 125000003373 pyrazinyl group Chemical group 0.000 claims description 3
- 238000002560 therapeutic procedure Methods 0.000 abstract description 5
- 238000002648 combination therapy Methods 0.000 abstract description 2
- 239000002136 L01XE07 - Lapatinib Substances 0.000 description 86
- 229960004891 lapatinib Drugs 0.000 description 86
- BCFGMOOMADDAQU-UHFFFAOYSA-N lapatinib Chemical compound O1C(CNCCS(=O)(=O)C)=CC=C1C1=CC=C(N=CN=C2NC=3C=C(Cl)C(OCC=4C=C(F)C=CC=4)=CC=3)C2=C1 BCFGMOOMADDAQU-UHFFFAOYSA-N 0.000 description 86
- 210000004027 cell Anatomy 0.000 description 67
- 102000003745 Hepatocyte Growth Factor Human genes 0.000 description 51
- 108090000100 Hepatocyte Growth Factor Proteins 0.000 description 51
- 210000004881 tumor cell Anatomy 0.000 description 45
- 230000000694 effects Effects 0.000 description 33
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 description 29
- 230000010261 cell growth Effects 0.000 description 29
- 230000017095 negative regulation of cell growth Effects 0.000 description 21
- 102100029986 Receptor tyrosine-protein kinase erbB-3 Human genes 0.000 description 19
- 230000005764 inhibitory process Effects 0.000 description 19
- 101100067974 Arabidopsis thaliana POP2 gene Proteins 0.000 description 15
- 102000001301 EGF receptor Human genes 0.000 description 15
- 101100118549 Homo sapiens EGFR gene Proteins 0.000 description 15
- 108090000556 Neuregulin-1 Proteins 0.000 description 15
- 102000048238 Neuregulin-1 Human genes 0.000 description 15
- 101100123851 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) HER1 gene Proteins 0.000 description 15
- XGALLCVXEZPNRQ-UHFFFAOYSA-N gefitinib Chemical compound C=12C=C(OCCCN3CCOCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 XGALLCVXEZPNRQ-UHFFFAOYSA-N 0.000 description 15
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 14
- 239000005411 L01XE02 - Gefitinib Substances 0.000 description 14
- 239000012091 fetal bovine serum Substances 0.000 description 14
- 230000026731 phosphorylation Effects 0.000 description 14
- 238000006366 phosphorylation reaction Methods 0.000 description 14
- 108090000623 proteins and genes Proteins 0.000 description 14
- 229960002584 gefitinib Drugs 0.000 description 13
- 230000002401 inhibitory effect Effects 0.000 description 13
- 239000005551 L01XE03 - Erlotinib Substances 0.000 description 12
- 102100037236 Tyrosine-protein kinase receptor UFO Human genes 0.000 description 12
- AAKJLRGGTJKAMG-UHFFFAOYSA-N erlotinib Chemical compound C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 AAKJLRGGTJKAMG-UHFFFAOYSA-N 0.000 description 12
- 239000003795 chemical substances by application Substances 0.000 description 11
- 229960001433 erlotinib Drugs 0.000 description 11
- 102000004169 proteins and genes Human genes 0.000 description 11
- 210000003739 neck Anatomy 0.000 description 10
- 238000003199 nucleic acid amplification method Methods 0.000 description 10
- 230000002018 overexpression Effects 0.000 description 10
- 238000001262 western blot Methods 0.000 description 10
- 230000006907 apoptotic process Effects 0.000 description 9
- 230000004913 activation Effects 0.000 description 8
- 238000004458 analytical method Methods 0.000 description 8
- 238000012360 testing method Methods 0.000 description 8
- 230000014509 gene expression Effects 0.000 description 7
- 239000001963 growth medium Substances 0.000 description 7
- 230000003321 amplification Effects 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- 230000035945 sensitivity Effects 0.000 description 6
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 5
- 230000005754 cellular signaling Effects 0.000 description 5
- 230000006882 induction of apoptosis Effects 0.000 description 5
- 208000020816 lung neoplasm Diseases 0.000 description 5
- 208000037841 lung tumor Diseases 0.000 description 5
- 230000035772 mutation Effects 0.000 description 5
- 230000004044 response Effects 0.000 description 5
- 230000002195 synergetic effect Effects 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- 102000011727 Caspases Human genes 0.000 description 4
- 108010076667 Caspases Proteins 0.000 description 4
- 102000009465 Growth Factor Receptors Human genes 0.000 description 4
- 108010009202 Growth Factor Receptors Proteins 0.000 description 4
- 108091000080 Phosphotransferase Proteins 0.000 description 4
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 4
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 4
- 239000012980 RPMI-1640 medium Substances 0.000 description 4
- 230000000996 additive effect Effects 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 231100000673 dose–response relationship Toxicity 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 description 4
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 description 4
- 238000013467 fragmentation Methods 0.000 description 4
- 238000006062 fragmentation reaction Methods 0.000 description 4
- 239000012458 free base Substances 0.000 description 4
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 4
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- 238000010208 microarray analysis Methods 0.000 description 4
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 description 4
- 102000020233 phosphotransferase Human genes 0.000 description 4
- 230000003389 potentiating effect Effects 0.000 description 4
- 238000009097 single-agent therapy Methods 0.000 description 4
- 210000003491 skin Anatomy 0.000 description 4
- 102000006311 Cyclin D1 Human genes 0.000 description 3
- 108010058546 Cyclin D1 Proteins 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 102000007665 Extracellular Signal-Regulated MAP Kinases Human genes 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 108700020796 Oncogene Proteins 0.000 description 3
- 102100033810 RAC-alpha serine/threonine-protein kinase Human genes 0.000 description 3
- 125000000217 alkyl group Chemical group 0.000 description 3
- 230000000903 blocking effect Effects 0.000 description 3
- 230000030833 cell death Effects 0.000 description 3
- 239000013592 cell lysate Substances 0.000 description 3
- 230000000875 corresponding effect Effects 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 210000003128 head Anatomy 0.000 description 3
- 239000003446 ligand Substances 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 210000001672 ovary Anatomy 0.000 description 3
- 230000011664 signaling Effects 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 2
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- 102000047934 Caspase-3/7 Human genes 0.000 description 2
- 108700037887 Caspase-3/7 Proteins 0.000 description 2
- 206010009944 Colon cancer Diseases 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 108010007457 Extracellular Signal-Regulated MAP Kinases Proteins 0.000 description 2
- 206010061968 Gastric neoplasm Diseases 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 102000004877 Insulin Human genes 0.000 description 2
- 108090001061 Insulin Proteins 0.000 description 2
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- SUHOOTKUPISOBE-UHFFFAOYSA-N O-phosphoethanolamine Chemical compound NCCOP(O)(O)=O SUHOOTKUPISOBE-UHFFFAOYSA-N 0.000 description 2
- 206010061535 Ovarian neoplasm Diseases 0.000 description 2
- 229920001213 Polysorbate 20 Polymers 0.000 description 2
- 108091008611 Protein Kinase B Proteins 0.000 description 2
- 229940124639 Selective inhibitor Drugs 0.000 description 2
- 102000004338 Transferrin Human genes 0.000 description 2
- 108090000901 Transferrin Proteins 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 238000000540 analysis of variance Methods 0.000 description 2
- 230000008485 antagonism Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 201000008275 breast carcinoma Diseases 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 238000013043 cell viability test Methods 0.000 description 2
- 210000001072 colon Anatomy 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 210000003238 esophagus Anatomy 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 206010017758 gastric cancer Diseases 0.000 description 2
- 208000010749 gastric carcinoma Diseases 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 229960000890 hydrocortisone Drugs 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 229940125396 insulin Drugs 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 229940084651 iressa Drugs 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 230000017066 negative regulation of growth Effects 0.000 description 2
- 208000025402 neoplasm of esophagus Diseases 0.000 description 2
- 230000001537 neural effect Effects 0.000 description 2
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 2
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 150000003384 small molecules Chemical class 0.000 description 2
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
- DAEPDZWVDSPTHF-UHFFFAOYSA-M sodium pyruvate Chemical compound [Na+].CC(=O)C([O-])=O DAEPDZWVDSPTHF-UHFFFAOYSA-M 0.000 description 2
- 201000000498 stomach carcinoma Diseases 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 210000001685 thyroid gland Anatomy 0.000 description 2
- 239000012581 transferrin Substances 0.000 description 2
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- AOUOVFRSCMDPFA-QSDJMHMYSA-N (2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-amino-3-carboxypropanoyl]amino]-4-carboxybutanoyl]amino]-3-methylbutanoyl]amino]butanedioic acid Chemical group OC(=O)C[C@@H](C(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](N)CC(O)=O AOUOVFRSCMDPFA-QSDJMHMYSA-N 0.000 description 1
- GMDWHBVEZCVCHU-UHFFFAOYSA-N 2-(2-methoxyethoxy)quinazolin-4-amine Chemical compound C1=CC=CC2=NC(OCCOC)=NC(N)=C21 GMDWHBVEZCVCHU-UHFFFAOYSA-N 0.000 description 1
- UKFTXWKNVSVVCJ-UHFFFAOYSA-N 2-[(6-hydrazinylpyridazin-3-yl)-(2-hydroxyethyl)amino]ethanol;hydron;dichloride Chemical class Cl.Cl.NNC1=CC=C(N(CCO)CCO)N=N1 UKFTXWKNVSVVCJ-UHFFFAOYSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- FWMBEYDLDLJTDP-UHFFFAOYSA-N 2-iodoquinazoline Chemical class C1=CC=CC2=NC(I)=NC=C21 FWMBEYDLDLJTDP-UHFFFAOYSA-N 0.000 description 1
- 125000004180 3-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(F)=C1[H] 0.000 description 1
- 102100022014 Angiopoietin-1 receptor Human genes 0.000 description 1
- 206010055113 Breast cancer metastatic Diseases 0.000 description 1
- DRSHXJFUUPIBHX-UHFFFAOYSA-N COc1ccc(cc1)N1N=CC2C=NC(Nc3cc(OC)c(OC)c(OCCCN4CCN(C)CC4)c3)=NC12 Chemical compound COc1ccc(cc1)N1N=CC2C=NC(Nc3cc(OC)c(OC)c(OCCCN4CCN(C)CC4)c3)=NC12 DRSHXJFUUPIBHX-UHFFFAOYSA-N 0.000 description 1
- GAGWJHPBXLXJQN-UORFTKCHSA-N Capecitabine Chemical compound C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1[C@H]1[C@H](O)[C@H](O)[C@@H](C)O1 GAGWJHPBXLXJQN-UORFTKCHSA-N 0.000 description 1
- GAGWJHPBXLXJQN-UHFFFAOYSA-N Capecitabine Natural products C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1C1C(O)C(O)C(C)O1 GAGWJHPBXLXJQN-UHFFFAOYSA-N 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 208000017897 Carcinoma of esophagus Diseases 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 108090000397 Caspase 3 Proteins 0.000 description 1
- 108090000567 Caspase 7 Proteins 0.000 description 1
- 102100029855 Caspase-3 Human genes 0.000 description 1
- 102100038902 Caspase-7 Human genes 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 230000004544 DNA amplification Effects 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 101150039808 Egfr gene Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 229940125497 HER2 kinase inhibitor Drugs 0.000 description 1
- 101000753291 Homo sapiens Angiopoietin-1 receptor Proteins 0.000 description 1
- 101000851181 Homo sapiens Epidermal growth factor receptor Proteins 0.000 description 1
- 101000898034 Homo sapiens Hepatocyte growth factor Proteins 0.000 description 1
- 101000932478 Homo sapiens Receptor-type tyrosine-protein kinase FLT3 Proteins 0.000 description 1
- 229930182816 L-glutamine Natural products 0.000 description 1
- 108060001084 Luciferase Proteins 0.000 description 1
- 239000005089 Luciferase Substances 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 102000019149 MAP kinase activity proteins Human genes 0.000 description 1
- 108040008097 MAP kinase activity proteins Proteins 0.000 description 1
- 102100021435 Macrophage-stimulating protein receptor Human genes 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 102000003992 Peroxidases Human genes 0.000 description 1
- 102000001938 Plasminogen Activators Human genes 0.000 description 1
- 108010001014 Plasminogen Activators Proteins 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 1
- 102100029981 Receptor tyrosine-protein kinase erbB-4 Human genes 0.000 description 1
- 101710100963 Receptor tyrosine-protein kinase erbB-4 Proteins 0.000 description 1
- 102100020718 Receptor-type tyrosine-protein kinase FLT3 Human genes 0.000 description 1
- 101100331535 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) DIB1 gene Proteins 0.000 description 1
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 1
- 108010090804 Streptavidin Proteins 0.000 description 1
- AUYYCJSJGJYCDS-LBPRGKRZSA-N Thyrolar Chemical compound IC1=CC(C[C@H](N)C(O)=O)=CC(I)=C1OC1=CC=C(O)C(I)=C1 AUYYCJSJGJYCDS-LBPRGKRZSA-N 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
- 102000016548 Vascular Endothelial Growth Factor Receptor-1 Human genes 0.000 description 1
- 108010053096 Vascular Endothelial Growth Factor Receptor-1 Proteins 0.000 description 1
- 102000016549 Vascular Endothelial Growth Factor Receptor-2 Human genes 0.000 description 1
- 108010053099 Vascular Endothelial Growth Factor Receptor-2 Proteins 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 230000019552 anatomical structure morphogenesis Effects 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000002583 anti-histone Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 238000003782 apoptosis assay Methods 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- KVSLPQXJQYNHIK-UHFFFAOYSA-N c1ccc2ncncc2c1.Cc1ccc(cc1)S(O)(=O)=O.Cc1ccc(cc1)S(O)(=O)=O Chemical compound c1ccc2ncncc2c1.Cc1ccc(cc1)S(O)(=O)=O.Cc1ccc(cc1)S(O)(=O)=O KVSLPQXJQYNHIK-UHFFFAOYSA-N 0.000 description 1
- 229960004117 capecitabine Drugs 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 201000011529 cardiovascular cancer Diseases 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 230000006037 cell lysis Effects 0.000 description 1
- 239000008004 cell lysis buffer Substances 0.000 description 1
- 238000012054 celltiter-glo Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 229940000425 combination drug Drugs 0.000 description 1
- 230000002301 combined effect Effects 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 230000003412 degenerative effect Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 238000006471 dimerization reaction Methods 0.000 description 1
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 1
- BVTBRVFYZUCAKH-UHFFFAOYSA-L disodium selenite Chemical compound [Na+].[Na+].[O-][Se]([O-])=O BVTBRVFYZUCAKH-UHFFFAOYSA-L 0.000 description 1
- 229960003668 docetaxel Drugs 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000000890 drug combination Substances 0.000 description 1
- 229940121647 egfr inhibitor Drugs 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 230000013020 embryo development Effects 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 108700020302 erbB-2 Genes Proteins 0.000 description 1
- 229940082789 erbitux Drugs 0.000 description 1
- 201000005619 esophageal carcinoma Diseases 0.000 description 1
- 229960005309 estradiol Drugs 0.000 description 1
- DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 description 1
- 229940047127 fiore Drugs 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 201000003911 head and neck carcinoma Diseases 0.000 description 1
- 229940022353 herceptin Drugs 0.000 description 1
- 102000057308 human HGF Human genes 0.000 description 1
- 229940127121 immunoconjugate Drugs 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000012606 in vitro cell culture Methods 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 238000003331 infrared imaging Methods 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 108020001756 ligand binding domains Proteins 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 201000005296 lung carcinoma Diseases 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- 230000002297 mitogenic effect Effects 0.000 description 1
- 230000004899 motility Effects 0.000 description 1
- 230000027405 negative regulation of phosphorylation Effects 0.000 description 1
- 230000009826 neoplastic cell growth Effects 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 1
- 230000006548 oncogenic transformation Effects 0.000 description 1
- 238000010422 painting Methods 0.000 description 1
- 230000003076 paracrine Effects 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 229940127126 plasminogen activator Drugs 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- 238000010837 poor prognosis Methods 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 230000005522 programmed cell death Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 125000002572 propoxy group Chemical group [*]OC([H])([H])C(C([H])([H])[H])([H])[H] 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 208000023958 prostate neoplasm Diseases 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 102000027426 receptor tyrosine kinases Human genes 0.000 description 1
- 108091008598 receptor tyrosine kinases Proteins 0.000 description 1
- 230000025915 regulation of apoptotic process Effects 0.000 description 1
- 230000009703 regulation of cell differentiation Effects 0.000 description 1
- 230000021014 regulation of cell growth Effects 0.000 description 1
- 230000025053 regulation of cell proliferation Effects 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- 229910052711 selenium Inorganic materials 0.000 description 1
- 239000011669 selenium Substances 0.000 description 1
- 229940091258 selenium supplement Drugs 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000012679 serum free medium Substances 0.000 description 1
- 229940054269 sodium pyruvate Drugs 0.000 description 1
- 229960001471 sodium selenite Drugs 0.000 description 1
- 235000015921 sodium selenite Nutrition 0.000 description 1
- 239000011781 sodium selenite Substances 0.000 description 1
- 238000009331 sowing Methods 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 206010041823 squamous cell carcinoma Diseases 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 230000009469 supplementation Effects 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 229940120982 tarceva Drugs 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 229940035722 triiodothyronine Drugs 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 1
- 239000005483 tyrosine kinase inhibitor Substances 0.000 description 1
- 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 210000003932 urinary bladder Anatomy 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- LSGOVYNHVSXFFJ-UHFFFAOYSA-N vanadate(3-) Chemical compound [O-][V]([O-])([O-])=O LSGOVYNHVSXFFJ-UHFFFAOYSA-N 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US5032208P | 2008-05-05 | 2008-05-05 | |
| PCT/US2009/042768 WO2009137429A1 (en) | 2008-05-05 | 2009-05-05 | Method of treating cancer using a cmet and axl inhibitor and an erbb inhibitor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2010012101A true MX2010012101A (es) | 2010-11-30 |
Family
ID=41257222
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2010012101A MX2010012101A (es) | 2008-05-05 | 2009-05-05 | Metodo de tratamiento del cancer usando un inhibidor de cmet y axl y un inhibidor de erbb. |
Country Status (19)
| Country | Link |
|---|---|
| US (3) | US20090274693A1 (enExample) |
| EP (1) | EP2274304A4 (enExample) |
| JP (1) | JP2011519941A (enExample) |
| KR (1) | KR20110004462A (enExample) |
| CN (1) | CN102083824A (enExample) |
| AR (1) | AR071631A1 (enExample) |
| AU (1) | AU2009244453B2 (enExample) |
| BR (1) | BRPI0912582A2 (enExample) |
| CA (1) | CA2723699A1 (enExample) |
| CL (1) | CL2009001063A1 (enExample) |
| EA (1) | EA020779B1 (enExample) |
| IL (1) | IL209057A0 (enExample) |
| MX (1) | MX2010012101A (enExample) |
| PE (1) | PE20091832A1 (enExample) |
| SG (1) | SG190623A1 (enExample) |
| TW (1) | TW201006829A (enExample) |
| UY (1) | UY31800A (enExample) |
| WO (1) | WO2009137429A1 (enExample) |
| ZA (1) | ZA201007722B (enExample) |
Families Citing this family (64)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5688877B2 (ja) | 2005-11-11 | 2015-03-25 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 癌疾患の治療用キナゾリン誘導体 |
| DK2387563T4 (da) | 2009-01-16 | 2022-07-18 | Exelixis Inc | Malatsalt af n-(4-{ [ 6, 7-bis(methyloxy)quinolin-4-yl]oxy}phenyl-n'-(4-fluorphenyl)cyclopropan-1,1-dicarboxamid, og krystallinske former deraf til behandling af cancer |
| RU2568066C2 (ru) | 2009-03-25 | 2015-11-10 | Дженентек, Инк. | Антитела против fgfr3 и способы их применения |
| JP5963672B2 (ja) | 2009-07-06 | 2016-08-03 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Ｂｉｂｗ２９９２、その塩及びこの活性成分を含む固体医薬製剤の乾燥方法 |
| TW201106972A (en) * | 2009-07-27 | 2011-03-01 | Genentech Inc | Combination treatments |
| WO2011014872A2 (en) * | 2009-07-31 | 2011-02-03 | The Johns Hopkins University | Compositions and methods for diagnosing, treating or preventing neoplasias |
| UA108618C2 (uk) | 2009-08-07 | 2015-05-25 | Застосування c-met-модуляторів в комбінації з темозоломідом та/або променевою терапією для лікування раку | |
| LT2719708T (lt) * | 2009-11-13 | 2018-02-12 | Daiichi Sankyo Europe Gmbh | Medžiaga ir būdai, skirti su her-3 susijusių ligų gydymui arba prevencijai |
| EP2593090B1 (en) | 2010-07-16 | 2021-10-13 | Exelixis, Inc. | C-met modulator pharmaceutical compositions |
| MY162825A (en) | 2010-08-20 | 2017-07-31 | Novartis Ag | Antibodies for epidermal growth factor receptor 3 (her3) |
| TW201302793A (zh) | 2010-09-03 | 2013-01-16 | Glaxo Group Ltd | 新穎之抗原結合蛋白 |
| FI2621481T4 (fi) | 2010-09-27 | 2023-01-13 | Met- ja vegf-kaksoisestäjiä kastraatioresistentin eturauhassyövän ja osteoblastisten luun etäispesäkkeiden hoitamiseen | |
| SG10201510086VA (en) * | 2010-12-23 | 2016-01-28 | Nestec Sa | Drug selection for malignant cancer therapy using antibody-based arrays |
| CN102532109B (zh) * | 2010-12-27 | 2015-05-13 | 浙江海正药业股份有限公司 | 一种拉帕替尼及其盐的合成方法 |
| CN102093421B (zh) * | 2011-01-28 | 2014-07-02 | 北京康辰药业有限公司 | 一种含磷取代基的喹啉类化合物及其制备方法、以及含有该化合物的药物组合物及其应用 |
| EA033513B1 (ru) | 2011-02-10 | 2019-10-31 | Exelixis Inc | Способы получения хинолиновых соединений и фармацевтических композиций, содержащих такие соединения |
| US20120252840A1 (en) | 2011-04-04 | 2012-10-04 | Exelixis, Inc. | Method of Treating Cancer |
| BR212013028314U2 (pt) * | 2011-05-02 | 2015-11-03 | Exelixis Inc | método para tratar câncer e dor de câncer de osso |
| EP2758057B1 (en) | 2011-09-22 | 2017-05-31 | Exelixis, Inc. | Method for treating osteoporosis |
| PT2768796T (pt) | 2011-10-20 | 2020-02-21 | Exelixis Inc | Processo para a preparação de derivados de quinolina |
| EP3045453A1 (en) * | 2011-11-14 | 2016-07-20 | Cephalon, Inc. | Uracil derivatives as axl and c-met kinase inhibitors |
| WO2013084147A2 (en) * | 2011-12-05 | 2013-06-13 | Novartis Ag | Antibodies for epidermal growth factor receptor 3 (her3) |
| TWI594986B (zh) | 2011-12-28 | 2017-08-11 | Taiho Pharmaceutical Co Ltd | Antineoplastic agent effect enhancer |
| DK2810937T3 (en) | 2012-01-31 | 2017-03-13 | Daiichi Sankyo Co Ltd | PYRIDONE DERIVATIVES |
| EP2844254A1 (en) | 2012-05-02 | 2015-03-11 | Exelixis, Inc. | A dual met - vegf modulator for treating osteolytic bone metastases |
| CN103664879A (zh) * | 2012-09-17 | 2014-03-26 | 杨育新 | 一类治疗创伤性脑损伤疾病的化合物及其用途 |
| CN103705521A (zh) * | 2012-09-28 | 2014-04-09 | 韩冰 | 一类治疗脑梗塞的化合物及其用途 |
| WO2014093750A1 (en) * | 2012-12-14 | 2014-06-19 | Glaxosmithkline Llc | Method of administration and treatment |
| JP6389238B2 (ja) | 2013-03-15 | 2018-09-12 | エグゼリクシス， インコーポレイテッド | Ｎ−（４−｛［６，７−ビス（メンチルオキシ）キノリン−４−イル］オキシ｝フェニル）−ｎ’−（４−フルオロフェニル）サイクロプロペイン−１，１−ジカルボキシアミドのメタボライト |
| KR102060540B1 (ko) | 2013-04-03 | 2019-12-31 | 삼성전자주식회사 | 항 c-Met 항체 및 항 Ang2 항체를 포함하는 병용 투여용 약학 조성물 |
| US11564915B2 (en) | 2013-04-04 | 2023-01-31 | Exelixis, Inc. | Cabozantinib dosage form and use in the treatment of cancer |
| TWI649308B (zh) | 2013-07-24 | 2019-02-01 | 小野藥品工業股份有限公司 | 喹啉衍生物 |
| US10196446B2 (en) | 2013-10-14 | 2019-02-05 | Janssen Biotech, Inc. | Cysteine engineered fibronectin type III domain binding molecules |
| CA2938818C (en) | 2014-02-04 | 2023-03-07 | Astellas Pharma Inc. | Pharmaceutical composition comprising diamino heterocyclic carboxamide compound as active ingredient |
| MX384828B (es) | 2014-02-14 | 2025-03-14 | Exelixis Inc | Formas solidas cristalinas de n-{4-[(6,7-dimetoxiquinolin-4-il)oxi]fenil}-n'-(4-fluorofenil)ciclopropan-1,1-dicarboxamida, procesos para elaboracion y metodos de uso. |
| WO2015142928A1 (en) | 2014-03-17 | 2015-09-24 | Exelixis, Inc. | Dosing of cabozantinib formulations |
| KR102410696B1 (ko) * | 2014-04-03 | 2022-06-17 | 메르크 파텐트 게엠베하 | 암 치료법의 조합 |
| KR102223502B1 (ko) | 2014-05-09 | 2021-03-05 | 삼성전자주식회사 | 항 c-Met/항 EGFR/항 Her3 다중 특이 항체 및 이의 이용 |
| TWI723572B (zh) | 2014-07-07 | 2021-04-01 | 日商第一三共股份有限公司 | 具有四氫吡喃基甲基之吡啶酮衍生物及其用途 |
| EP3174854B1 (en) | 2014-07-31 | 2022-08-24 | Exelixis, Inc. | Method of preparing fluorine-18 labeled cabozantinib and its analogs |
| MA40457A (fr) | 2014-08-05 | 2017-06-14 | Exelixis Inc | Combinaison de médicaments pour traiter le myélome multiple |
| ES2749726T3 (es) | 2014-12-25 | 2020-03-23 | Ono Pharmaceutical Co | Derivado de quinolina |
| FR3039401B1 (fr) * | 2015-07-31 | 2018-07-13 | Les Laboratoires Servier | Nouvelle association entre le 3-[(3-{[4-(4-morpholinylmethyl)-1h-pyrrol-2-yl]methylene}-2-oxo-2,3-dihydro-1h-indol-5-yl)methyl]-1,3-thiazolidine-2,4-dione et un inhibiteur de la tyr kinase du egfr |
| CN106467541B (zh) * | 2015-08-18 | 2019-04-05 | 暨南大学 | 取代喹诺酮类衍生物或其药学上可接受的盐或立体异构体及其药用组合物和应用 |
| CA3020749A1 (en) | 2016-04-15 | 2017-10-19 | Exelixis, Inc. | Method of treating renal cell carcinoma using n-(4-(6,7-dimethoxyquinolin-4-yloxy) phenyl)-n'-(4-fluoropheny)cyclopropane-1,1-dicarboxamide, (2s)-hydroxybutanedioate |
| MX2018016185A (es) | 2016-06-21 | 2019-03-28 | Janssen Biotech Inc | Moléculas de unión al dominio de fibronectina tipo iii diseñadas de cisteína. |
| CN107235896B (zh) * | 2016-09-13 | 2019-11-05 | 上海翔锦生物科技有限公司 | 酪氨酸激酶抑制剂及其应用 |
| CN107235897B (zh) * | 2016-09-27 | 2019-08-16 | 上海翔锦生物科技有限公司 | 酪氨酸激酶抑制剂及其应用 |
| AU2017378226A1 (en) | 2016-12-14 | 2019-06-20 | Janssen Biotech, Inc. | CD8A-binding fibronectin type III domains |
| WO2018111976A1 (en) | 2016-12-14 | 2018-06-21 | Janssen Biotech, Inc. | Pd-l1 binding fibronectin type iii domains |
| EP3554561B1 (en) | 2016-12-14 | 2023-06-28 | Janssen Biotech, Inc. | Cd137 binding fibronectin type iii domains |
| HUE054883T2 (hu) | 2017-01-26 | 2021-10-28 | Ono Pharmaceutical Co | N-{5-[(6,7-dimetoxi-4-kinolinil)oxi]-2-piridinil}-2,5-dioxo-1-fenil-1,2,5,6,7,8-hexahidro-3-kinolinkarboxamid etánszulfonát sója |
| MY194278A (en) | 2017-02-15 | 2022-11-25 | Taiho Pharmaceutical Co Ltd | Pharmaceutical composition |
| EP3682882A4 (en) | 2017-09-08 | 2021-06-02 | Taiho Pharmaceutical Co., Ltd. | ANTI-TUMOR AGENT AND ANTI-TUMOR POTENTIALIZER |
| WO2019074116A1 (ja) | 2017-10-13 | 2019-04-18 | 小野薬品工業株式会社 | Ａｘｌ阻害剤を有効成分として含む固形がん治療剤 |
| CN113292537B (zh) | 2018-06-15 | 2024-04-05 | 汉达癌症医药责任有限公司 | 激酶抑制剂的盐类及其组合物 |
| AU2020210863B2 (en) * | 2019-01-25 | 2025-10-23 | Exelixis, Inc. | Compounds for the treatment of kinase-dependent disorders |
| EP4045061A4 (en) | 2019-10-14 | 2024-04-17 | ARO Biotherapeutics Company | FIBRONECTIN TYPE III DOMAINS BINDING TO CD137 |
| US12491255B2 (en) | 2019-10-14 | 2025-12-09 | Aro Biotherapeutics Company | EPCAM binding fibronectin type III domains |
| WO2021076574A2 (en) | 2019-10-14 | 2021-04-22 | Aro Biotherapeutics Company | Fn3 domain-sirna conjugates and uses thereof |
| CN115073367A (zh) * | 2021-03-16 | 2022-09-20 | 南京科默生物医药有限公司 | 一种用作axl抑制剂的抗肿瘤化合物及其用途 |
| BR112023021318A2 (pt) | 2021-04-14 | 2023-12-19 | Aro Biotherapeutics Company | Conjugados de domínio fn3-sirna e usos dos mesmos |
| CA3214552A1 (en) | 2021-04-14 | 2022-10-20 | Russell C. Addis | Cd71 binding fibronectin type iii domains |
| CN120417903A (zh) | 2023-01-31 | 2025-08-01 | 汉达癌症医药责任有限公司 | 改良的卡博替尼组合物及其使用方法 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE290882T1 (de) * | 2001-01-16 | 2005-04-15 | Glaxo Group Ltd | Pharmazeutische mischung gegen krebs, die ein 4- chinazolinamin in kombination mit paclitaxel, carboplatin or vinorelbine enthält |
| CA2744997A1 (en) * | 2003-09-26 | 2005-04-07 | Exelixis, Inc. | C-met modulators and method of use |
| ITRM20030475A1 (it) * | 2003-10-15 | 2005-04-16 | Sipa Societa Industrializzazione P Rogettazione E | Impianto e metodo per il condizionamento termico di oggetti |
| UA96139C2 (uk) * | 2005-11-08 | 2011-10-10 | Дженентек, Інк. | Антитіло до нейропіліну-1 (nrp1) |
| US20090123474A1 (en) * | 2005-12-15 | 2009-05-14 | Astrazeneca Ab | Combination of angiopoietin-2 antagonist and of vegf-a, kdr and/or fltl antagonist for treating cancer |
| WO2007081978A2 (en) * | 2006-01-11 | 2007-07-19 | Angion Biomedica Corporation | Modulators of hepatocyte growth factor / c-met activity |
| CN105106199A (zh) * | 2006-12-14 | 2015-12-02 | 埃克塞利希斯股份有限公司 | 使用mek抑制剂的方法 |
| EP2851091B1 (en) * | 2007-04-13 | 2017-12-27 | Dana-Farber Cancer Institute, Inc. | Methods for treating cancer resistant to ERBB therapeutics |
| CN101743253B (zh) * | 2007-05-17 | 2013-05-08 | 健泰科生物技术公司 | 神经毡蛋白片段与神经毡蛋白抗体复合物的晶体结构 |
| WO2009017838A2 (en) * | 2007-08-01 | 2009-02-05 | Exelixis, Inc. | Combinations of jak-2 inhibitors and other agents |
| HRP20160949T1 (hr) * | 2007-09-10 | 2016-10-07 | Boston Biomedical, Inc. | Novi sastavi i metode za liječenje karcinoma |
-
2009
- 2009-04-30 UY UY0001031800A patent/UY31800A/es not_active Application Discontinuation
- 2009-05-04 PE PE2009000602A patent/PE20091832A1/es not_active Application Discontinuation
- 2009-05-04 CL CL2009001063A patent/CL2009001063A1/es unknown
- 2009-05-04 TW TW098114669A patent/TW201006829A/zh unknown
- 2009-05-05 SG SG2013033709A patent/SG190623A1/en unknown
- 2009-05-05 US US12/435,473 patent/US20090274693A1/en not_active Abandoned
- 2009-05-05 CA CA2723699A patent/CA2723699A1/en not_active Abandoned
- 2009-05-05 EP EP09743415A patent/EP2274304A4/en not_active Withdrawn
- 2009-05-05 CN CN2009801261595A patent/CN102083824A/zh active Pending
- 2009-05-05 EA EA201071268A patent/EA020779B1/ru not_active IP Right Cessation
- 2009-05-05 AR ARP090101611A patent/AR071631A1/es unknown
- 2009-05-05 JP JP2011508584A patent/JP2011519941A/ja active Pending
- 2009-05-05 MX MX2010012101A patent/MX2010012101A/es not_active Application Discontinuation
- 2009-05-05 KR KR1020107027183A patent/KR20110004462A/ko not_active Ceased
- 2009-05-05 WO PCT/US2009/042768 patent/WO2009137429A1/en not_active Ceased
- 2009-05-05 AU AU2009244453A patent/AU2009244453B2/en not_active Ceased
- 2009-05-05 BR BRPI0912582-5A patent/BRPI0912582A2/pt not_active IP Right Cessation
-
2010
- 2010-10-28 ZA ZA2010/07722A patent/ZA201007722B/en unknown
- 2010-11-01 IL IL209057A patent/IL209057A0/en unknown
-
2013
- 2013-01-29 US US13/753,031 patent/US20130142790A1/en not_active Abandoned
- 2013-01-29 US US13/753,146 patent/US20130150363A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US20130150363A1 (en) | 2013-06-13 |
| JP2011519941A (ja) | 2011-07-14 |
| AU2009244453B2 (en) | 2012-07-19 |
| CL2009001063A1 (es) | 2010-09-24 |
| TW201006829A (en) | 2010-02-16 |
| PE20091832A1 (es) | 2009-12-25 |
| CN102083824A (zh) | 2011-06-01 |
| EA201071268A1 (ru) | 2011-06-30 |
| US20090274693A1 (en) | 2009-11-05 |
| KR20110004462A (ko) | 2011-01-13 |
| US20130142790A1 (en) | 2013-06-06 |
| AU2009244453A1 (en) | 2009-11-12 |
| EP2274304A1 (en) | 2011-01-19 |
| BRPI0912582A2 (pt) | 2015-07-28 |
| UY31800A (es) | 2009-11-10 |
| IL209057A0 (en) | 2011-01-31 |
| WO2009137429A1 (en) | 2009-11-12 |
| CA2723699A1 (en) | 2009-11-12 |
| ZA201007722B (en) | 2011-08-31 |
| AR071631A1 (es) | 2010-06-30 |
| EA020779B1 (ru) | 2015-01-30 |
| SG190623A1 (en) | 2013-06-28 |
| EP2274304A4 (en) | 2012-05-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2009244453B2 (en) | Method of treating cancer using a cMET and AXL inhibitor and an erbB inhibitor | |
| Wheeler et al. | Epidermal growth factor receptor cooperates with Src family kinases in acquired resistance to cetuximab | |
| AU2019407426A1 (en) | Combination of antibody-drug conjugate and kinase inhibitor | |
| JPWO2006090930A1 (ja) | スルホンアミド化合物の新規併用 | |
| US10011659B2 (en) | Compositions and methods for treating cancer resistant to a tyrosine kinase inhibitor (TKI) | |
| KR20140025433A (ko) | Ａｋｔ 억제제 화합물 및 베무라페닙의 조합물, 및 사용 방법 | |
| JP2022027658A (ja) | チロシンキナーゼ阻害剤と併用してｅｇｆ／ｅｇｆｒ経路を抑制する方法および組成物 | |
| WO2020005934A1 (en) | Poziotinib combinations with an anti-her1, her2 or her4 antibody and methods of use thereof | |
| EP3176183A1 (en) | Compositions and methods for treating cancer not resistant to a tyrosine kinase inhibitor (tki) | |
| US20140056910A1 (en) | Therapeutic agent for cancer having reduced sensitivity to molecular target drug and pharmaceutical composition for enhancing sensitivity to molecular target drug | |
| US20230321087A1 (en) | Fgfr inhibitor combination therapies | |
| WO2025238176A1 (en) | Combinations of egfr/erb and bet inhibitors for gastric cancer | |
| Sorbera et al. | Deforolimus | |
| HK40054690A (en) | Combination of antibody-drug conjugate and kinase inhibitor | |
| HK40044450A (en) | Poziotinib combinations with an anti-her1, her2 or her4 antibody and methods of use thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |